Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2026
Patient group calls faster rare disease drug reimbursement process a 'meaningful start'
8 June 2026 - Patient advocacy groups have welcomed the Government's plan to shorten the reimbursement listing period for rare ...
Posted by Michael Wonder on 07 Jun 2026
Vyloy, Fintepla and Rybrevant move closer to reimbursement after passing HIRA review
5 June 2026 - Several new therapies for serious and rare diseases have moved a step closer to receiving national ...
Posted by Michael Wonder on 05 Jun 2026
J&J Innovative Medicine Korea wins reimbursement for Darzalex SC regimen in newly diagnosed AL amyloidosis
4 June 2026 - Johnson & Johnson Innovative Medicine Korea said Darzalex subcutaneous injection-based quadruple regimen has received reimbursement in ...
Posted by Michael Wonder on 02 Jun 2026
GSK secures Omjjara reimbursement in Korea, expanding access for myelofibrosis patients
1 June 2026 - GSK Korea said Monday that its myelofibrosis treatment Omjjara (momelotinib hydrochloride hydrate) has been granted reimbursement ...
Posted by Michael Wonder on 01 Jun 2026
BMS Korea expands Pomalyst reimbursement to secpnd-line multiple myeloma treatment
29 May 2026 - Bristol Myers Squibb Korea said its Pomalyst (pomalidomide)-based triple therapy will become reimbursable from 1 June ...
Posted by Michael Wonder on 29 May 2026
AbbVie’s Elahere clears first reimbursement hurdle for platinum-resistant ovarian cancer in Korea
28 May 2026 - AbbVie’s ovarian cancer drug Elahere has cleared its first hurdle toward reimbursement coverage in Korea, potentially ...
Posted by Michael Wonder on 25 May 2026
Novo’s Sogroya gets Korea reimbursement for growth hormone deficiency
22 May 2026 - Novo Nordisk Pharma Korea said Thursday its once weekly growth hormone therapy Sogroya has received national ...
Posted by Michael Wonder on 22 May 2026
After decade-long climb in Korea, AstraZeneca’s Tagrisso hits access wall
19 May 2026 - AstraZeneca’s Tagrisso has become strong enough in early EGFR mutated lung cancer that Korean doctors say ...
Posted by Michael Wonder on 21 May 2026
Neurofibromatosis patients push for adult reimbursement of Koselugo
19 May 2026 - Patients with neurofibromatosis are calling for insurance reimbursement to be expanded to adult patients for the ...
Posted by Michael Wonder on 09 May 2026
Lilly's Retevmo moves closer to Korea reimbursement coverage after key review approval
8 May 2026 - Retevmo (selpercatinib), a targeted therapy for RET gene mutation-driven cancers, has cleared a major hurdle toward ...
Posted by Michael Wonder on 08 May 2026
Korea begins insurance coverage for Novo Nordisk’s weekly growth hormone drug
6 May 2026 - Some children and adults in Korea with growth hormone deficiency can now receive Novo Nordisk’s once ...
Posted by Michael Wonder on 08 May 2026
AZ's Imfinzi wins reimbursement for first-line BTC, HCC treatment in Korea
3 March 2026 - AstraZeneca Korea said Tuesday that Imfinzi (durvalumab) is now covered by national health insurance as of ...
Posted by Michael Wonder on 04 May 2026
Korea covers Takeda’s Takhzyro, but most patients may still be left out: experts
26 March 2026 - Korea has granted reimbursement for Takeda’s hereditary angioedema drug Takhzyro (lanadelumab), but physicians say most patients ...
Posted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides ...
Posted by Michael Wonder on 04 Apr 2026
US hikes tariffs on Korean patented drugs, spares biosimilars for year
3 April 2026 - Korean drug makers eye US manufacturing labels and limited exemptions as Washington targets patented meds with new ...